Peroxisome proliferator-activated receptor γ ligands induce growth inhibition and apoptosis of human B lymphocytic leukemia

Leukemia Research

Volumn 28, Issue 4, 2004, Pages 387-397

  Zang, Chuanbing ^a   Liu, Hongyu ^a   Posch, Maximilian G ^a   Waechter, Maries ^a   Facklam, Margit ^a   Fenner, Martin H ^a   Ruthardt, Martin ^b   Possinger, Kurt ^a   Koeffler, H Phillip ^c   Elstner, Elena ^a  

^a HUMBOLDT UNIVERSITY   (Germany)

^b GOETHE UNIVERSITY   (Germany)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Acute lymphocytic leukemia; Apoptosis; Peroxisome proliferator activated receptor ; Pioglitazone; Proliferation

Indexed keywords

15 DEOXY DELTA12,14 PROSTAGLANDIN J2; CASPASE INHIBITOR; CYCLIN D1; CYCLIN D2; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; PROTEIN P27;

ACUTE LYMPHOCYTIC LEUKEMIA; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL DIFFERENTIATION; CELL GROWTH; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; GENE MUTATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; UPREGULATION;

EID: 10744219838     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2003.07.005     Document Type: Article

References (53)

1. Hoelzer D., Gokbuget N. New approaches to acute lymphoblastic leukemia in adults: where do we go? Semin. Oncol. 27:2000;540-559.
2. Forman B., Tontonoz P., Chen J., Brun R., Spiegelman B., Evans R. 15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma. Cell. 83:1995;803-812.
3. Kliewer S., Lenhard J., Willson T., Patel I., Morris D., Lehmann J. A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation. Cell. 83:1995;813-819.
4. Berger J., Bailey P., Biswas C., Cullinan C., Doebber T., Hayes N.et al. Thiazolidinediones produce a conformational change in peroxisomal proliferator-activated receptor-gamma: binding and activation correlate with antidiabetic actions in db/db mice. Endocrinology. 137:1996;4189-4195.
5. Lehmann J., Moore L., Smith-Oliver T., Wilkison W., Willson T., Kliewer S. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J. Biol. Chem. 270:1995;12953-12956.
6. Chawla A., Schwarz E., Dimaculangan D., Lazar M. Peroxisome proliferator-activated receptor (PPAR) gamma: adipose-predominant expression and induction early in adipocyte differentiation. Endocrinology. 135:1994;798-800.
7. Tontonoz P., Graves R., Budavari A., Erdjument-Bromage H., Lui M., Hu E.et al. Adipocyte-specific transcription factor ARF6 is a heterodimeric complex of two nuclear hormone receptors, PPAR gamma and RXR alpha. Nucleic. Acids. Res. 22:1994;5628-5634.
8. Brun R., Kim J., Hu E., Spiegelman B. Peroxisome proliferator-activated receptor gamma and the control of adipogenesis. Curr. Opin. Lipidol. 8:1997;212-218.
9. Spiegelman B. PPAR-gamma: adipogenic regulator and thiazolidinedione receptor. Diabetes. 47:1998;507-514.
10. Hupfeld C., Weiss R. TZDs inhibit vascular smooth muscle cell growth independently of the cyclin kinase inhibitors p21 and p27. Am. J. Physiol. Endocrinol. Metabol. 281:2001;E207-E216.
11. Kawa S., Nikaido T., Unno H., Usuda N., Nakayama K., Kiyosawa K. Growth inhibition and differentiation of pancreatic cancer cell lines by PPAR gamma ligand troglitazone. Pancreas. 24:2002;1-7.
12. Konopleva M., Andreeff M. Role of peroxisome proliferator-activated receptor-gamma in hematologic malignancies. Curr. Opin. Hematol. 9:2002;294-302.
13. Takahashi N., Okumura T., Motomura W., Fujimoto Y., Kawabata I., Kohgo Y. Activation of PPARgamma inhibits cell growth and induces apoptosis in human gastric cancer cells. FEBS Lett. 455:1999;135-139.
14. Chang T., Szabo E. Induction of differentiation and apoptosis by ligands of peroxisome proliferator-activated receptor gamma in non-small cell lung cancer. Cancer Res. 60:2000;1129-1138.
15. Tsubouchi Y., Sano H., Kawahito Y., Mukai S., Yamada R., Kohno M.et al. Inhibition of human lung cancer cell growth by the peroxisome proliferator-activated receptor-gamma agonists through induction of apoptosis. Biochem. Biophys. Res. Commun. 270:2000;400-405.
16. Chattopadhyay N., Singh D., Heese O., Godbole M., Sinohara T., Black P. et al. Expression of peroxisome proliferator-activated receptors (PPARS) in human astrocytic cells: PPARgamma agonists as inducers of apoptosis. J. Neurosci. Res. 61:2000;67-74.
17. Zander T., Kraus J., Grommes C., Schlegel U., Feinstein D., Klockgether T.et al. Induction of apoptosis in human and rat glioma by agonists of the nuclear receptor PPARgamma. J. Neurochem. 81:2002;1052-1060.
18. Tontonoz P., Singer S., Forman B., Sarraf P., Fletcher J., Fletcher C.et al. Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor gamma and the retinoid X receptor. Proc. Natl. Acad. Sci. U.S.A. 94:1997;237-241.
19. Demetri G., Fletcher C., Mueller E., Sarraf P., Naujoks R., Campbell N. et al. Induction of solid tumor differentiation by the peroxisome proliferator- activated receptor-gamma ligand troglitazone in patients with liposarcoma. Proc. Natl. Acad. Sci. U.S.A. 96:1999;3951-3956.
20. Kubota T., Koshizuka K., Williamson E., Asou H., Said J., Holden S.et al. Ligand for peroxisome proliferator-activated receptor gamma (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo. Cancer Res. 58:1998;3344-3352.
21. Mueller E., Smith M., Sarraf P., Kroll T., Aiyer A., Kaufman D.et al. Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancer. Proc. Natl. Acad. Sci. U.S.A. 97:2000;10990-10995.
22. Brockman J., Gupta R., Dubois R. Activation of PPARgamma leads to inhibition of anchorage-independent growth of human colorectal cancer cells. Gastroenterology. 115:1998;1049-1055.
23. Sarraf P., Mueller E., Jones D., King F., DeAngelo D., Partridge J.et al. Differentiation and reversal of malignant changes in colon cancer through PPARgamma. Nat. Med. 4:1998;1046-1052.
24. Kitamura S., Miyazaki Y., Shinomura Y., Kondo S., Kanayama S., Matsuzawa Y. Peroxisome proliferator-activated receptor gamma induces growth arrest and differentiation markers of human colon cancer cells. Jpn. J. Cancer Res. 90:1999;75-80.
25. Yang W., Frucht H. Activation of the PPAR pathway induces apoptosis and COX-2 inhibition in HT-29 human colon cancer cells. Carcinogenesis. 22:2001;1379-1383.
26. Elstner E., Mueller C., Koshizuka K., Williamson E., Park D., Asou H.et al. Ligands for peroxisome proliferator-activated receptorgamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc. Natl. Acad. Sci. U.S.A. 95:1998;8806-8811.
27. Kilgore M., Tate P., Rai S., Sengoku E., Price T. MCF-7 and T47D human breast cancer cells contain a functional peroxisomal response. Mol. Cell. Endocrinol. 129:1997;229-235.
28. Mueller E., Sarraf P., Tontonoz P., Evans R., Martin K., Zhang M.et al. Terminal differentiation of human breast cancer through PPAR gamma. Mol. Cell. 1:1998;465-470.
29. Sato H., Ishihara S., Kawashima K., Moriyama N., Suetsugu H., Kazumori H.et al. Expression of peroxisome proliferator-activated receptor (PPAR)gamma in gastric cancer and inhibitory effects of PPARgamma agonists. Br. J. Cancer. 83:2000;1394-1400.
30. KiP1 in human pancreatic carcinoma cells. Cancer Res. 60:2000;5558-5564.
31. Elnemr A., Ohta T., Iwata K., Ninomia I., Fushida S., Nishimura G.et al. PPARgamma ligand (thiazolidinedione) induces growth arrest and differentiation markers of human pancreatic cancer cells. Int. J. Oncol. 17:2000;1157-1164.
32. Asou H., Verbeek W., Williamson E., Elstner E., Kubota T., Kamada N.et al. Growth inhibition of myeloid leukemia cells by troglitazone, a ligand for peroxisome proliferator activated receptor gamma, and retinoids. Int. J. Oncol. 15:1999;1027-1031.
33. Drexler H., MacLeod R., Uphoff C. Leukemia cell lines: in vitro models for the study of Philadelphia chromosome-positive leukemia. Leuk. Res. 23:1999;207-215.
34. Drexler H., Dirks W., MacLeod R. False human hematopoietic cell lines: cross-contaminations and misinterpretations. Leukemia. 13:1999;1601-1607.
35. PE Biosystems. Rlative quantitation of gene expression. ABI Prism 7700 Sequence Detection System. 1997.
36. Cobb J., Blanchard S., Boswell E., Brown K., Charifson P., Cooper J.et al. N-(2-benzoylphenyl)-L-tyrosine PPARgamma agonists. 3. Structure-activity relationship and optimization of the N-aryl substituent. J. Med. Chem. 41:1998;5055-5069.
37. Yin F., Wakino S., Liu Z., Kim S., Hsueh W., Collins A.et al. Troglitazone inhibits growth of MCF-7 breast carcinoma cells by targeting G1 cell cycle regulators. Biochem. Biophys. Res. Commun. 286:2001;916-922.
38. King K., Cidlowski J. Cell cycle regulation and apoptosis. Ann. Rev. Physiol. 60:1998;601-617.
39. Bishop-Bailey D., Hla T. Endothelial cell apoptosis induced by the peroxisome proliferator-activated receptor (PPAR) ligand 15-deoxy-Delta12, 14-prostaglandin J2. J. Biol. Chem. 274:1999;17042-17048.
40. Patel L., Pass I., Coxon P., Downes C., Smith S., Macphee C. Tumor suppressor and anti-inflammatory actions of PPARgamma agonists are mediated via upregulation of PTEN. Curr. Biol. 11:2001;764-768.
41. Tsao T., Konopleva M., Sporn M., Andreeff M. Targeted induction of apoptosis in leukemias by PPARg ligation. Blood. 98:2002;568a-569a.
42. Chawla A., Barak Y., Nagy L., Liao D., Tontonoz P., Evans R. PPAR-gamma dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation. Nat. Med. 7:2001;48-52.
43. Palakurthi S., Aktas H., Grubissich L., Mortensen R., Halperin J. Anticancer effects of thiazolidinediones are independent of peroxisome proliferator-activated receptor gamma and mediated by inhibition of translation initiation. Cancer Res. 61:2001;6213-6218.
44. Clay C., Namen A., Atsumi G., Willingham M., High K., Kute T.et al. Influence of J series prostaglandins on apoptosis and tumorigenesis of breast cancer cells. Carcinogenesis. 20:1999;1905-1911.
45. Rumi M., Sato H., Ishihara S., Kawashima K., Hamamoto S., Kazumori H.et al. Peroxisome proliferator-activated receptor gamma ligand-induced growth inhibition of human hepatocellular carcinoma. Br. J. Cancer. 84:2001;1640-1647.
46. Sugimura A., Kiriyama Y., Nochi H., Tsuchiya H., Tamoto K., Sakurada Y. et al. Troglitazone suppresses cell growth of myeloid leukemia cell lines by induction of p21WAF1/CIP1 cyclin-dependent kinase inhibitor. Biochem. Biophys. Res. Commun. 261:1999;833-837.
47. Wakino S., Kintscher U., Kim S., Yin F., Hsueh W., Law R. Peroxisome proliferator-activated receptor gamma ligands inhibit retinoblastoma phosphorylation and. G1→S transition in vascular smooth muscle cells J. Biol. Chem. 275:2000;22435-22441.
48. Wolowiec D, Ciszak L, Kosmaczewska A, Bocko D, Teodorowska R, Frydecka I, et al. Cell cycle regulatory proteins and apoptosis in B-cell chronic lymphocytic leukemia. Haematologica 2001;86(12)1296-1304.
49. Decker T, Schneller F, Hipp S, Miething C, Jahn T, Duyster J. et al. Cell cycle progression of chronic lymphocytic leukemia cells is controlled by cyclin D2, cyclin D3, cyclin-dependent kinase (cdk) 4 and the cdk inhibitor p27, Leukemia 2002;16(3):327-34.
50. Laurora S, Pizzimenti S, Briatore F, Fraioli A, Maggio M, Reffo P, et al. Peroxisome proliferator-activated receptor ligands affect growth-related gene expression in human leukemic cells, J. Pharmacol. Exp. Ther. 2003;305(3):932-42.
51. Chinetti G., Griglio S., Antonucci M., Torra I., Delerive P., Majd Z.et al. Activation of proliferator-activated receptors alpha and gamma induces apoptosis of human monocyte-derived macrophages. J. Biol. Chem. 273:1998;25573-25580.
52. Susin S., Daugas E., Ravagnan L., Samejima K., Zamzami N., Loeffler M.et al. Two distinct pathways leading to nuclear apoptosis. J. Exp. Med. 192:2000;571-580.
53. Foghsgaard L., Wissing D., Mauch D., Lademann U., Bastholm L., Boes M.et al. Cathepsin B acts as a dominant execution protease in tumor cell apoptosis induced by tumor necrosis factor. J. Cell Biol. 153:2001;999-1010.